Shridhar, V <br/><br/>
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.  [electronic resource] 

 -  Cancer research  May 2001 
 - 4258-65 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amino Acid Sequence<br/>Azacitidine--analogs & derivatives<br/>Base Sequence<br/>Chromosome Mapping<br/>Cisplatin--pharmacology<br/>Cloning, Molecular<br/>DNA, Neoplasm--genetics<br/>Decitabine<br/>Down-Regulation<br/>Drug Resistance, Multiple--genetics<br/>Drug Resistance, Neoplasm<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Gene Silencing<br/>HSP40 Heat-Shock Proteins<br/>Heat-Shock Proteins--biosynthesis<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Loss of Heterozygosity<br/>Molecular Sequence Data<br/>Ovarian Neoplasms--drug therapy<br/>Oximes<br/>Paclitaxel--pharmacology<br/>Piperazines<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Sequence Homology, Amino Acid<br/>Topotecan--pharmacology<br/>Transfection<br/>Tumor Cells, Cultured